Our current study extends the anti-inflammatory activity of rhPRG4 to controlling IL-1β secretion by PBMCs from patients with acute gout flares, where the efficacious rhPRG4 concentration was in the range of what was reported as efficacious in in vitro models of human synoviocytes, macrophages, endothelial and corneal epithelial cells. Here, IL1B is linked to gout.